<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> WSJ880112-0149 </DOCNO><HL> Praxis Biologics Gets a License </HL><SO> </SO><CO> PRXS </CO><DATELINE> ROCHESTER, N.Y.  </DATELINE><TEXT>   Praxis Biologics Inc., a research and biopharmaceutical products concern, said it received from the University of Rochester an exclusive license to a patent on the production and application of human monoclonal antibodies that can neutralize bacterial toxins. The price wasn't disclosed.    Praxis said it expects to negotiate multiple subleases for the technology with other companies. It said monoclonal antibodies, still in experimental therapy, could find broad use in treating human infections. </TEXT></DOC>